The first survodutide Phase 3 study in patients with MASH is estimated to be completed in June 2029, and the Phase 3 trial for NA-941 recently started
Useful tracking points include: Baseline eye exam status Existing AMD diagnosis or family history Diabetes status and HbA1c trend Blood pressure and lipid markers Smoking history GLP-1 medication, dose, and start date Speed of weight loss New visual symptoms, distortion, blurred central vision, floaters, or dark spots Ophthalmology follow-up dates and findings PeptIQ is not a replacement for an eye exam
The mechanisms are biologically plausible
Without targeted interventions to restore mitochondrial transport pathways and quench this raging oxidative fire, patients remain trapped in a devastating state of chronic cellular depletion and systemic hyper-reactivity, unable to break the cycle of fatigue and inflammation
Clinicians should also avoid or adjust therapy in individuals with active peptic ulcer disease due to theoretical choline-mediated increases in gastric volume and in those receiving levodopa, as pantothenic-acid derivatives may interfere with levodopa absorption